Giuseppe Sangiorgio, Maddalena Calvo, Stefania Stefani
{"title":"针对产生金属β-乳酰胺酶的革兰氏阴性菌的阿兹曲南和阿维菌素联合疗法：全面回顾。","authors":"Giuseppe Sangiorgio, Maddalena Calvo, Stefania Stefani","doi":"10.1016/j.cmi.2024.11.006","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Carbapenem-resistant Gram-negative bacteria represent a challenging healthcare threat, accounting for metallo-β-lactamases (MBL) production increase across the world. MBL-producing Enterobacterales and P. aeruginosa represent the main target for ultimate antibiotics combinations due to the difficulty to include carbapenems within the antimicrobial treatment.</p><p><strong>Objectives: </strong>To provide a comprehensive review of the current knowledge about the aztreonam/avibactam (ATM-AVI) combination, which has emerged as a promising option for treating MBL-producing bacteria. Sources Relevant in vitro and in vivo studies on ATM-AVI effectiveness.</p><p><strong>Content: </strong>The review summarizes ATM-AVI characteristics and targets, examining how avibactam restores aztreonam effectiveness against MBLs while protecting it from other β-lactamases. Key in vitro and in vivo studies on ATM-AVI efficacy are presented.</p><p><strong>Implications: </strong>This review provides insights into the potential clinical management implications of ATM-AVI for treating carbapenem-resistant Gram-negative infections, particularly those caused by MBL-producing organisms.</p>","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":""},"PeriodicalIF":10.9000,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Aztreonam and Avibactam Combination Therapy for Metallo-β-Lactamase-Producing Gram-Negative Bacteria: A Comprehensive Review.\",\"authors\":\"Giuseppe Sangiorgio, Maddalena Calvo, Stefania Stefani\",\"doi\":\"10.1016/j.cmi.2024.11.006\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Carbapenem-resistant Gram-negative bacteria represent a challenging healthcare threat, accounting for metallo-β-lactamases (MBL) production increase across the world. MBL-producing Enterobacterales and P. aeruginosa represent the main target for ultimate antibiotics combinations due to the difficulty to include carbapenems within the antimicrobial treatment.</p><p><strong>Objectives: </strong>To provide a comprehensive review of the current knowledge about the aztreonam/avibactam (ATM-AVI) combination, which has emerged as a promising option for treating MBL-producing bacteria. Sources Relevant in vitro and in vivo studies on ATM-AVI effectiveness.</p><p><strong>Content: </strong>The review summarizes ATM-AVI characteristics and targets, examining how avibactam restores aztreonam effectiveness against MBLs while protecting it from other β-lactamases. Key in vitro and in vivo studies on ATM-AVI efficacy are presented.</p><p><strong>Implications: </strong>This review provides insights into the potential clinical management implications of ATM-AVI for treating carbapenem-resistant Gram-negative infections, particularly those caused by MBL-producing organisms.</p>\",\"PeriodicalId\":10444,\"journal\":{\"name\":\"Clinical Microbiology and Infection\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":10.9000,\"publicationDate\":\"2024-11-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Microbiology and Infection\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.cmi.2024.11.006\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Microbiology and Infection","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.cmi.2024.11.006","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
Aztreonam and Avibactam Combination Therapy for Metallo-β-Lactamase-Producing Gram-Negative Bacteria: A Comprehensive Review.
Background: Carbapenem-resistant Gram-negative bacteria represent a challenging healthcare threat, accounting for metallo-β-lactamases (MBL) production increase across the world. MBL-producing Enterobacterales and P. aeruginosa represent the main target for ultimate antibiotics combinations due to the difficulty to include carbapenems within the antimicrobial treatment.
Objectives: To provide a comprehensive review of the current knowledge about the aztreonam/avibactam (ATM-AVI) combination, which has emerged as a promising option for treating MBL-producing bacteria. Sources Relevant in vitro and in vivo studies on ATM-AVI effectiveness.
Content: The review summarizes ATM-AVI characteristics and targets, examining how avibactam restores aztreonam effectiveness against MBLs while protecting it from other β-lactamases. Key in vitro and in vivo studies on ATM-AVI efficacy are presented.
Implications: This review provides insights into the potential clinical management implications of ATM-AVI for treating carbapenem-resistant Gram-negative infections, particularly those caused by MBL-producing organisms.
期刊介绍：
Clinical Microbiology and Infection (CMI) is a monthly journal published by the European Society of Clinical Microbiology and Infectious Diseases. It focuses on peer-reviewed papers covering basic and applied research in microbiology, infectious diseases, virology, parasitology, immunology, and epidemiology as they relate to therapy and diagnostics.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
